-
19 Apr 2018
19 April 2018: On the ‘back’ of successful AusBiotech investment events in Shanghai and Hong Kong, AusBiotech is deepening its relationship and work in China with a raft of activities, including an arrangement with China BlueSky Partners to represent AusBiotech to Chinese investors.
Read More
-
26 Sep 2017
26 September 2017: For a limited time, AusBiotech will host a China Market Desk, manned by Austrade Shanghai’s Senior Business Development Manager (BDM), Mr Andre Zhu.
Read More
-
13 Jun 2017
Biotron (ASX:BIT) has announced the appointment of Shanghai-based advisory group, Lynx Financial, as corporate advisor to assist with the execution of its China commercialisation strategy.
Read More
-
13 Jun 2017
CSL has agreed to acquire an 80 per cent stake in plasma-derived therapies manufacturer Wuhan Zhong Yuan Rui De Biological Products ('Ruide') from the Humanwell Healthcare Group for US$352 million.
Read More
-
13 Apr 2017
The AusBiotech-led Asian Investment Series has confirmed investor interest in the Australian life science industry is strong and intensifying.
Read More
-
16 Feb 2017
Emerging life science companies are encouraged to take advantage of Asia’s propitious investment landscape and join AusBiotech’s Asian Investment Series.
Read More
